876372-63-3Relevant academic research and scientific papers
Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition
Jerome, Kevin D.,Rucker, Paul V.,Xing, Li,Shieh, Huey S.,Baldus, John E.,Selness, Shaun R.,Letavic, Michael A.,Braganza, John F.,McClure, Kim F.
scheme or table, p. 469 - 473 (2010/04/05)
The structure based drug design, synthesis and structure-activity relationship of a series of C6 sulfur linked triazolopyridine based p38 inhibitors are described. The metabolic deficiencies of this series were overcome through changes in the C6 linker fr
NOVEL TRIAZOLOPYRIDINE COMPOUNDS
-
Page/Page column 94; 95, (2008/06/13)
This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): wherein R
NOVEL TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
-
Page/Page column 111, (2008/06/13)
This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): Wherein R1, R2, R3, R4, and R5are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
